Biotech Values

[DewDiligence]

DARE—Latest in long list of companies seeking a treatment for FSAD:

https://www.globenewswire.com/news-release/2021/03/24/2198408/30757/en/Dar%C3%A9-Bioscience-Announces-Initiation-of-Phase-2b-RESPOND-Study-of-Sildenafil-Cream-3-6-in-Women-with-Female-Sexual-Arousal-Disorder.html

Daré Bioscience, a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD).

Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, being developed as a first-in-category option for the treatment of FSAD. FSAD is the inability to reach or maintain a sufficient physical response to sexual stimulation and, of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men.

The post I’m replying to is from 15 years ago!